Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Biologics in Rheumatology: Revolution & Perspectives

  |  

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. G Horneff, GR Burmester, F Emmrich, et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum. 1991. 34(2):129–140.
  2. K Albrecht, D Huscher, T Eidner, et al. Medical treatment of rheumatoid arthritis in 2014: Current data from the German Collaborative Arthritis Centers. Z Rheumatol. 2017 Feb;76(1):50–57.

Related Articles

    Phase 2 Results for Mavrilimumab Are In

    Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating…